Drug Profile
Tobramycin oral - Enteris BioPharma
Alternative Names: Tobramycin sulfate oral - Enteris BioPharma; Tobrate®Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Enteris BioPharma
- Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Urinary tract infections
Most Recent Events
- 28 Feb 2024 RRD International is now called RRD Biopharma Development
- 28 Aug 2021 No recent reports of development identified for phase-I development in Urinary-tract-infections(In volunteers) in USA (PO, Tablet)
- 28 Aug 2019 No recent reports of development identified for phase-I development in Urinary-tract-infections(In volunteers) in USA (PO, Tablet)